Latest Insider Transactions at Phathom Pharmaceuticals, Inc. (PHAT)
This section provides a real-time view of insider transactions for Phathom Pharmaceuticals, Inc. (PHAT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phathom Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phathom Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2023
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+8.07%
|
-
|
|
Nov 01
2023
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+11.84%
|
-
|
|
Jul 14
2023
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+34.42%
|
-
|
|
Jul 14
2023
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+33.92%
|
-
|
|
Jul 14
2023
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.8%
|
$25,000
$1.0 P/Share
|
|
Jun 02
2023
|
Asit Parikh |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+24.0%
|
$105,000
$7.4 P/Share
|
|
Jun 02
2023
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
1,960
-2.78%
|
$21,560
$11.41 P/Share
|
|
May 25
2023
|
Mark Stenhouse |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
May 25
2023
|
James N Topper |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+29.42%
|
-
|
|
May 25
2023
|
Asit Parikh |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+21.69%
|
-
|
|
May 25
2023
|
David A Socks |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
May 25
2023
|
Heidi Fields |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
May 25
2023
|
Michael F Cola |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+32.38%
|
-
|
|
May 25
2023
|
Frank Karbe |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
May 22
2023
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
2,110
-2.91%
|
$25,320
$12.87 P/Share
|
|
Apr 11
2023
|
Azmi Nabulsi Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+9.13%
|
$80,000
$8.26 P/Share
|
|
Apr 10
2023
|
Asit Parikh |
BUY
Open market or private purchase
|
Direct |
1,000
+4.08%
|
$7,000
$7.55 P/Share
|
|
Apr 06
2023
|
Terrie Curran President and Chief Executive |
BUY
Open market or private purchase
|
Direct |
12,919
+6.42%
|
$90,433
$7.82 P/Share
|
|
Apr 06
2023
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
3,439
-4.52%
|
$24,073
$7.27 P/Share
|
|
Mar 01
2023
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
2,032
-2.6%
|
$16,256
$8.53 P/Share
|
|
Mar 01
2023
|
Terrie Curran President and Chief Executive |
SELL
Open market or private sale
|
Direct |
1,436
-0.81%
|
$11,488
$8.54 P/Share
|
|
Feb 13
2023
|
Asit Parikh |
BUY
Open market or private purchase
|
Direct |
5,000
+18.18%
|
$35,000
$7.73 P/Share
|
|
Jan 20
2023
|
Terrie Curran President and Chief Executive |
SELL
Open market or private sale
|
Direct |
5,821
-3.19%
|
$46,568
$8.2 P/Share
|
|
Jan 19
2023
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+34.81%
|
-
|
|
Jan 19
2023
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+33.44%
|
-
|
|
Jan 19
2023
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+29.72%
|
-
|
|
Jan 12
2023
|
Asit Parikh |
BUY
Open market or private purchase
|
Direct |
5,000
+22.22%
|
$35,000
$7.0 P/Share
|
|
Nov 21
2022
|
Terrie Curran President and Chief Executive |
SELL
Open market or private sale
|
Direct |
1,526
-1.79%
|
$13,734
$9.6 P/Share
|
|
Nov 21
2022
|
Molly Henderson CFO and CBO |
SELL
Open market or private sale
|
Direct |
2,159
-4.75%
|
$19,431
$9.6 P/Share
|
|
Sep 01
2022
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+15.16%
|
-
|
|
Sep 01
2022
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+14.15%
|
-
|
|
Sep 01
2022
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+8.09%
|
-
|
|
May 19
2022
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+13.54%
|
-
|
|
May 19
2022
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.0%
|
-
|
|
May 19
2022
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+26.44%
|
-
|
|
May 16
2022
|
Azmi Nabulsi Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
20,000
+2.48%
|
$160,000
$8.16 P/Share
|
|
May 13
2022
|
Molly Henderson CFO and CBO |
BUY
Open market or private purchase
|
Direct |
6,000
+18.75%
|
-
|
|
May 13
2022
|
Terrie Curran President and Chief Executive |
BUY
Open market or private purchase
|
Direct |
20,500
+24.09%
|
$143,500
$7.41 P/Share
|
|
May 12
2022
|
Asit Parikh |
BUY
Open market or private purchase
|
Direct |
12,500
+50.0%
|
$100,000
$8.0 P/Share
|
|
Apr 05
2022
|
Molly Henderson CFO and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Mar 14
2022
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
18
-0.0%
|
$342
$19.0 P/Share
|
|
Mar 14
2022
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
7,359,304
+49.66%
|
-
|
|
Jan 19
2022
|
Terrie Curran President and Chief Executive |
BUY
Grant, award, or other acquisition
|
Direct |
41,250
+48.33%
|
-
|
|
Jan 19
2022
|
Anthony J. Guzzo VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+41.67%
|
-
|
|
Jan 19
2022
|
Azmi Nabulsi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+47.7%
|
-
|
|
Nov 04
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,000,001
-45.45%
|
$19,000,019
$19.93 P/Share
|
|
Nov 04
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
228,696
+17.21%
|
-
|
|
Oct 08
2021
|
David A Socks |
SELL
Open market or private sale
|
Indirect |
2,529
-0.21%
|
$80,928
$32.05 P/Share
|
|
Oct 07
2021
|
David A Socks |
SELL
Open market or private sale
|
Indirect |
15,471
-1.26%
|
$495,072
$32.66 P/Share
|
|
Sep 22
2021
|
David A Socks |
SELL
Open market or private sale
|
Indirect |
4,100
-0.33%
|
$131,200
$32.06 P/Share
|